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ABSTRACT 
    
    The association between overt hypothyroidism and altered lipid profile is well known, whereas the 
significance of dyslipidemia in subclinical hypothyroidism (SCH) is still a matter of debate. The aim of 
the present study was to evaluate the lipid profile in patients with SCH in comparison to controls. Serum 
lipid parameters of 34 patients with SCH and 34 age- and sex-matched healthy controls were evaluated 
in our study. TC (198.88 ± 42.90 vs 171.40 ± 26.24 mg/dl, P < 0.01) and LDL-C concentrations (129.04 
± 35.44 vs 106.71 ± 26.21 mg/dl, P < 0.01) as well as ratio of LDL-C/HDL-C (3.51 ± 1.46 vs 2.81 ± 
0.80, P < 0.05) were significantly higher in the patients in comparison to the controls, whereas HDL-C 
and TC/HDL-C ratio remained unaltered. TG concentrations were higher in the patients but this 
difference did not reach statistical significance (0.063). Correlation analyses revealed a significant 
correlation of TSH with TC, LDL-C and LDL-C/HDL-C ratio (r=0.351, r=0.345, r=0.340, respectively, 
P < 0.01) and a borderline correlation with TG (p=0.051). Our findings showed that SCH is associated 
with some lipid abnormalities suggesting higher risk of cardiovascular disease in these patients which 
seems to weigh in favor of treatment of patients with SCH. 
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INTRODUCTION  
     Subclinical hypothyroidism (SCH), also called 
mild thyroid failure, is characterized by elevated 
levels of serum thyroid stimulating hormone 
(TSH) in the presence of normal thyroxine (T4) 
and triiodothyronine (T3) levels [1]. This 
condition is one of the most common endocrine 
disorders that occur in 4 to 20 percent of the 
general population [2]. The prevalence increases 
with age and is higher in women [3]. SCH has 
clinical significance because of its high 
prevalence, the risk of progression to overt 
hypothyroidism (OH), poor quality of life related 
to nonspecific symptoms and potential 
consequences including neurobehavioral and 
cardiovascular disorders [4, 5]. Cardiovascular 
outcome in these patients is partly due to its 
association with unfavorable lipid profile. Thyroid 
hormones have varied effects on lipid metabolism, 
because thyroid function regulates lipids synthesis 
and degradation and mediates the activity of key 
enzymes in these pathways [6, 7]. The association 
between OH and dyslipidemia is well known [6], 
which may predispose to the development of 
cardiovascular disease (CVD), however it is 
uncertain whether SCH is also associated with 
lipid abnormalities [1, 8, 9]. Substantial studies on 
the association between SCH and lipid 
abnormalities have been conducted but results 
from these studies are not consistent [10]. In this 
respect, it has been reported that SCH is 
associated with increased levels of total 
cholesterol (TC), low density lipoprotein-
cholesterol (LDL-C) and triglyceride (TG) [11, 
12] and decreased levels of high density 
lipoprotein- cholesterol (HDL-C) [13]. However, 
some of the literature has reported no difference in 
the lipid parameters between SCH and healthy 
subjects [14]. The decision about whether to 
screen patients for this disorder is clouded by 
inconsistent evidence of association of lipid 
abnormalities or other risk factors of CVD with 
 




SCH. In the presence of dyslipidemia, screening 
and treatment for SCH has been suggested to 
prevent CVD [4]. 
The aim of the present study was to assess the 
effect of SCH on fasting serum lipids in patients 
with SCH. 
 
MATERIALS AND METHODS  
Subjects 
    Thirty-four newly diagnosed SCH patients (30 
women and 4 men) aged 36.20 ± 9.77 years from 
the endocrine clinic of Taleghani Hospital and 
Endocrine Research Center, and 34 sex- and age-
matched euthyroid healthy controls were included 
to the study according to the inclusion and 
exclusion criteria mentioned below. Diagnosis of 
SCH was based on the finding of high TSH levels 
associated with normal T4 levels. 
Inclusion criteria 
    Newly diagnosed individuals with SCH based 
on TSH level between 6-10µIU/ml and normal T4 
value 4.9-12.5 µg/dl. Age and sex matched 
euthyroid subjects having normal TSH and T4 
values. 
Exclusion criteria 
    The patients who were diagnosed as 
hyperthyroid and hypothyroid were not included 
in this study. None of the participants was 
diagnosed with diabetes mellitus or other 
endocrine disease such as polycystic ovary 
syndrome, renal and hepatic dysfunction, heart 
failure, stroke or ischemic heart disease or other 
systemic diseases, primary or secondary 
dyslipidemia. Subjects receiving drugs known to 
cause SCH and affect lipid metabolism were 
excluded from the study. The protocol of study 
was approved by the Research Ethic Committee of 
Shahid Beheshti University of Medical Sciences 
and after a clear explanation of the study protocol. 
Each participant gave a written informed consent 
to participate.  
Laboratory Procedures  
      After 12 hours overnight fasting, blood 
samples were collected from all participants for 
measuring biochemical parameters. The samples 
were immediately centrifuged at 3000 rpm for 5 
min and serum was separated. The sera were 
stored at -20° C until assayed. 
Serum T3, T4 and TSH levels were measured by 
the enzyme-linked immunosorbent assay (ELISA) 
method using commercial kits (Diaplus INC, 
USA). The intra-assay coefficient of variations 
(CVs) for T3, T4 and TSH were 4.1%, 4.1%, and 
4.2%, respectively, and the inter assay CVs were 
4.3%, 5.2% and 4.6%, respectively. The 
sensitivity of the assay was 0.4 ng/ dl, 0.4 µg/ dl 
and 0.078 µIU/ ml, respectively. The normal range 
for TSH is 0.39-5.95 µIU/ml and for T3 and T4 
are 55-200 ng/ dl and 4.9-12.5 µg/ dl, respectively. 
Serum levels of TC, TG and HDL-C were 
measured using a spectrophotometric assay with 
commercial kits (Pars Azmoon, Tehran, Iran) at 
546 nm. Intra assay CVs for TC, TG and HDL-C 
were 1.4%, 1.61% and 1.04%, respectively. 
Serum levels of TC and TG were determined by 
enzymatic colorimetric assay using CHOD-PAP 
and GPO-PAP method, respectively. HDL-C was 
determined enzymatically in the supernatant after 
dextran–magnesium-induced precipitation of other 
lipoproteins. LDL-C was calculated using the 
Friedewald formula: LDL-C= serum total 
cholesterol –HDL cholesterol – one-fifth of the 
TG concentration [15]. The TC-to- HDL-C and 
LDL-C- to- HDL-C ratios were also calculated. 
Statistical Analysis 
     All data were presented as mean± standard 
deviation and were evaluated with the 
Kolmogrov-Smirnov test for normality. 
Independent- t test was used for the comparison of 
mean values between control and patient groups. 
Pearson’s correlation coefficient was used to 
evaluate the correlations between two variables. 
For all the tests, p-value less than 0.05 was 
considered as statistically significant. Statistical 
analyses were conducted using the Statistical 
Package for Social Sciences (SPSS) version 22. 
 
RESULTS 
      In this study, 34 patients with SCH and 34 
healthy subjects were analyzed. They were 36.20 
± 9.77 vs 36.38 ± 9.62 years old. There were not 
any differences in age (P=0.940) and gender 
between SCH and control group. The results of 
TSH, T3 and T4 are summarized in Table1. As 
seen, compared with the healthy control group, 
TSH level was significantly higher in the SCH 
patients (7.13 ± 3.43 vs 2.55 ± 1.36 µIU/ ml, P < 
0.001). T4 concentrations was significantly 
(P=0.026) lower in the patients, while T3 levels 
showed no significant difference in the SCH 
patients compared with the healthy subjects (P = 
0.855). Differences in lipid status between SCH 
and control group are shown in Table 2. Subjects 
with SCH had significantly higher levels of TC 
and LDL-C as compared with the healthy 
individuals (198.88 ± 42.90 vs 171.40 ± 26.24 
mg/dl, 129.04 ± 35.44 vs 106.71 ± 26.21 mg/dl, 
respectively, P<0.01). LDL-C/HDL-C ratio was 
 




also higher in the patients compared with the 
controls (3.51 ± 1.46 vs 2.81 ± 0.80, P<0.05). 
Serum concentrations of TG were higher in the 
SCH patients when compared with the controls, 
but this differences did not reach the limit of 
significance (P= 0.063). There were no significant 
differences in HDL-C and ratio of TC/ HDL-C 
between patients with SCH and controls (P = 
0.602, P= 0.335, respectively). 
The Pearson’s correlation coefficients for the 
relationships between TSH and lipid parameters 
are shown in Table 3. Our study showed that TSH 
levels were positively correlated with TC, LDL-C 
and ratio of LDL-C/HDL-C (r=0.351, r=0.345, 
r=0.340, respectively, for all cases P=0.004). 
Moreover, we also observed borderline 
association between TG levels and TSH (r=0.251, 
P=0.051). TSH was not significantly correlated 
with HDL-C and ratio of TC/ HDL-C. 
 
Table 1. Hormonal status of the subclinical hypothyroidism patients and healthy controls  
Variable 
 






TSH, µIU/ml 7.13 ± 3.43 2.55 ± 1.36 0.000** 
T4, µg/dl 5.06 ± 2.19 6.02 ± 1.18 0.026* 
T3, ng/dl 97.12 ± 26.15 98.15 ± 20.53 0.855 
Data are expressed as mean ± standard deviation. TSH: thyroid-stimulating hormone; T4: tetraiodothyronine; T3; 
triiodothyronine. 
*Statistically significant. 
* P<0.05, **P <0.001.  
 
Table2. Lipid parameters of the groups involved in the study  
Variable 
 





Age, years 36.20 ± 9.77 36.38 ± 9.62 0.940 
TC, mg/dl 198.88 ± 42.90 171.40 ± 26.24 0.003** 
LDL-C,  mg/dl 129.04 ± 35.44 106.71 ± 26.21 0.004** 
HDL-C, mg/dl 40.48 ±12.46 39.12 ± 8.76 0.602 
TG, mg/dl 146.76 ± 71.70 119.44 ± 38.53 0.063 
LDL-C/HDL-C ratio 3.51 ± 1.46 2.81 ± 0.80 0.018* 
TC /HDL-C ratio 5.18 ± 2.50 4.71 ± 1.29 0.335 
Data are expressed as mean ± standard deviation. TC: total cholesterol; LDL-C: low density lipoprotein- cholesterol; HDL-C: 
high density lipoprotein- cholesterol; TG: triglyceride.   
*Statistically significant. 
* P<0.05, ** P <0.01.  
 




p value r values  
0.004* 0.351 TC 
0.004* 0.345 LDL-C 
0.841 -0.025 HDL-C  
0.051 0.251 TG 
0.004* 0.340 LDL-C/HDL-C ratio 
0.105 0.197 TC/HDL-C ratio 
TSH: thyroid-stimulating hormone; TC: total cholesterol; LDL-C: low density lipoprotein- cholesterol; HDL-C: high density 
lipoprotein- cholesterol; TG: triglyceride.   
 *Statistically significant. P <0.01. 
 
DISCUSSION 
  OH is associated with increased risk of CVD 
[16], while evidence regarding the association 
of SCH and the risk of CVD appear conflicting 
in previous studies [16-22]. Increased risk for 
atherosclerosis and CV disorders in 
hypothyroidism can be attributed primarily to 
dyslipidaemia. Although there was a clear 
relationship between dyslipidemia and OH [6], 
the significance of dyslipidemia in SCH 
especially in subjects with serum TSH levels 
less than 10 µIU/ ml remains controversial [1, 
23]. Some studies reported higher levels of TC 
or/and LDL-C in SCH subjects [24, 25], 
whereas others demonstrated no association of 
SCH and increased levels of TC and LDL-C [9, 
 




14]. These conflicting reports in the literature 
may be a result of differences in sex and age of 
patients and, the degree and duration of 
hypothyroidism, as well as differences in 
population studied. The Colorado Study 
revealed that patients with SCH had 
significantly higher TC and LDL-C 
concentrations compared with euthyroid 
subjects [26]. Consistently, findings from 
Tromso Study showed increased levels of LDL-
C in SCH subjects [27]. In line with the above, 
results from several smaller studies 
demonstrated an association between 
unfavorable lipid profile and SCH [12, 28, 29]. 
As in previous studies, our data revealed that 
patients with SCH had increased TC and LDL-
C levels compared with age and sex matched 
healthy subjects. Elevation of serum LDL-C and 
TC is due to decreased cholesterol excretion and 
mainly to impaired clearance of LDL, probably 
reflecting decreased LDL receptor expression 
[30]. By contrast, National Health and Nutrition 
Examination Survey III (NHANES III) reported 
no significant differences in lipid parameters in 
subjects with SCH compared with euthyroid 
individuals when adjusted for age and sex and 
the use of lipid-lowering agents [31]. The LDL-
C/HDL-C ratio is a better predictor for risk of 
heart disease than LDL-C alone [32]. In this 
regard, our data showed elevated LDL-C/ HDL-
C ratio in the SCH patients compared with the 
controls which is in agreement with Althaus et 
al study [33]. Luboshitzky et al concluded that 
SCH in middle-aged women is associated with 
hypertriglyceridemia and elevated TC/HDL-C 
ratio [8].  In contrast, our data showed no 
significant difference in TC/HDL-C ratio 
between SCH patients and controls. Some 
studies have indicated that SCH dyslipidemia 
may also be accompanied by increased TG 
levels [13]. In hypothyroidism, lipoprotein 
lipase activity in the adipose tissue has been 
shown normal or decreased, in addition to 
decreased hepatic lipase activity resulting in 
normal or increased levels of TG [34]. Toruner 
et al [11] have reported that the TG 
concentrations of SCH patients are higher than 
control subjects. As in previous studies, our data 
revealed that patients with SCH had higher TG 
levels compared with the healthy subjects but 
did not reach to the statistical significance. 
Small size of samples and short duration of 
illness state may be possible reasons for 
insignificancy of our result. There is also 
conflicting data with regard to the effect of SCH 
on HDL-C levels, since normal [1] as well as 
decreased levels [35] have been reported. Our 
data showed that the SCH and control groups 
did not differ in their HDL-C values. Elevated 
serum TSH values may be a risk factor for 
dyslipidemia and CV disease as we observed a 
significant positive correlation between TC, 
LDL-C, LDL-C/HDL-C ratio and TSH. A 
border line correlation between TG and TSH 
was also observed in our study. In agreement 
with our results, Iqbal et al revealed that serum 
TSH concentrations were positively correlated 
with TC and LDL-C levels [27]. Moreover, 
serum lipids may be significantly affected by 
thyroid function even in euthyroid individuals. 
In this regard, Lee et al study revealed a positive 
correlation of TSH within the normal range and 
TC, LDL-C and TG in subjects with no history 
of thyroid dysfunctions or relevant treatment, 
even after adjustment for age, sex and obesity 
[36]. Given the high prevalence of SCH in 
general population and association between 
dyslipidemia and TSH, screening of patients 
with dyslipidemia for thyroid dysfunction may 
be justifiable before starting hypolipidemic drug 
therapy. However, large-scale randomized 
studies are needed for evidence-based 
recommendations with respect to screening for 
mild thyroid failure and substitution therapy for 
this condition. It is currently uncertain whether 
SCH should be treated [37]. The evidence 
provided by different studies is controversial 
and concerns different aspects of this condition 
[38, 39].  
However, based on the data available, it appears 
that substitution therapy should be considered in 
patients with mild hypothyroidism in the 
presence of dyslipidemia and other associated 
CV risk factors in the attempt to reverse these 
undesirable prognostic factors [40].  
 
CONCLUSION  
    Our data showed that SCH is associated with 
some lipid abnormalities including higher levels 
of serum TC and LDL-C, which are risk factors 
for CVD. These findings could justify the 
increased risk of CVDs in subjects with SCH. 
Hence, based on the results of the current study, 
careful screening of subjects with SCH with 
respect to the dyslipidemia seems necessary and 
need to be addressed. However, further studies 
are needed to evaluate a larger series of patients, 
with a longer duration of SCH. 
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